Mitsuteru Natsuizaka

Sapporo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 80 publications

Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma.

Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma.

Journal: Hepatology international

Published: October 22, 2025

Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.

Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.

Journal: Targeted oncology

Published: August 14, 2024

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.

Journal: JHEP reports : innovation in hepatology

Published: August 04, 2024

Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study.

Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: July 23, 2024

Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC.

Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC.

Journal: Alimentary pharmacology & therapeutics

Published: June 09, 2024

Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma.

Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma.

Journal: Frontiers in nutrition

Published: August 04, 2023

Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.

Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.

Journal: Cancers

Published: May 21, 2023

Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.

Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: April 20, 2023

Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight.

Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: December 15, 2022

Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.

Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.

Journal: Cancers

Published: December 12, 2022

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.

Journal: Viruses

Published: December 10, 2022

Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.

Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.

Journal: Journal of medical virology

Published: September 16, 2022

Showing 1-12 of 80

Last Updated: 09/26/2026